SCHEMBL4629128

SCHEMBL4629128

CC(C)(C)OC(=O)N1CCCS1(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD11B1 P28845 1/20 0.40
CTSK P43235 1/20 0.40
HPGD P15428 1/20 0.38
EPHX1 P07099 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
PREP P48147 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HSD17B10 Q99714 1/20 0.33
RECQL P46063 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066309 0.80 USP2 (0.37) USP2SMN1; SMN2HSD11B1CTSKHPGD
SCHEMBL16617849 0.74 USP2 (0.45) USP2SMN1; SMN2HSD11B1CTSKHPGD
SCHEMBL25901635 0.73 NR1H2 (0.42) USP2SMN1; SMN2HPGDEPHX1CHRM2
SCHEMBL3461672 0.72 HPGD (0.50) USP2SMN1; SMN2HPGDEPHX1PREP
SCHEMBL9951801 0.71 HPGD (0.50) USP2SMN1; SMN2CTSKHPGDEPHX1
SCHEMBL17149731 0.71 HPGD (0.46) USP2SMN1; SMN2CTSKHPGDEPHX1
SCHEMBL2285414 0.71 CYP1A2 (0.36)
SCHEMBL1546414 0.71 USP2 (0.45) USP2SMN1; SMN2HPGDEPHX1CHRM2
SCHEMBL22574311 0.70 USP2 (0.41) USP2SMN1; SMN2HSD11B1CTSKHPGD
SCHEMBL30983085 0.70 HSD17B10 (0.34) USP2SMN1; SMN2CTSKHPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-106458994-A Biaryl kinase inhibitors 百时美施贵宝公司 2017-02-22 CN disclosed
EP-1917255-A2 INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-05-07 EP disclosed
WO-2007014851-A2 INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150974-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB USP2 2391/4885SMN1; SMN2 40/4885HSD11B1 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.